Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing I

1. Z isomer of 3-[(3-{[4-(4-Morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II):

having an X-ray powder diffractogram which exhibits the Bragg's angles 2 theta (expressed in terms of °+0.2) 12.86; 15.13; 15.50; 17.70; 18.25; 18.71; 20.11; 21.46; 21.67; 21.89; 22.29; 22.58; 24.57; 25.82; 26.33.

2. The compound according to claim 1 , which exhibits the following crystal parameters, obtained starting from the powder diffractogram carried out on a Panalytical Xpert-Pro MPD diffractometer (copper anticathode) in transmission mode with an angular range of 3-55° in terms of 2θ, a step of 0.017° and 35.5 s per step:

unit cell parameters: a=15.0958(5) Å, b=18.4586(6) Å, c=8.8269(2) Å, β=94.074(1)°, γ=90°

space group: C 1 c 1 (9)

volume of unit cell: V unit cell =2453.37600 Å 3 .

3. A process for obtaining the compound of formula (II) according to claim 1 , wherein 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione is dissolved in a binary system of solvent/water, to which solution from 1 to 2 molar equivalents of methanesulphonic acid are added, stirring until the methanesulphonate precipitates out, which precipitate is filtered off.

4. A process for obtaining the compound of formula (II) according to claim 1 , wherein 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione hydrochloride is dissolved in a binary system of solvent/water, the pH of which solution is brought to 8 by adding a base, the resulting salt is removed by filtration, the filtrate is then heated and methanesulphonic acid added, and the medium is stirred and cooled until the methanesulphonate precipitates out, which precipitate is filtered off.

5. A pharmaceutical composition comprising the compound of formula (II) according to claim 1 in combination with one or more pharmaceutically acceptable excipients.

6. A method of treating a condition selected from cancers of the colon, breast, liver, kidneys, brain and œsophagus, melanomas, myelomas, ovarian cancers, non-small-cell lung cancers, small-cell lung cancers, prostate and pancreatic cancers, and sarcomas in a subject in need thereof, comprising administration of a compound of formula II according to claim 1 to the subject, optionally in combination with one or more pharmaceutically acceptable excipients.

7. A combination of the compound of formula (II) according to claim 1 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.

8. A method of treating cancer in a subject in need thereof, comprising administration of a combination according to claim 7 to the subject.

9. A method of treating cancer in a subject in need thereof, comprising administration of a compound of formula (H) according to claim 1 to the subject in combination with radiotherapy.